Member Info for Matml74

LOL. He could see the writing on the wall!

Enrico, US based II's have to report at 5%.

“Finally, his introduction was a real touch of class.”

Wasn’t it just. This company is run by some very clever and humble people who seem to have all bases covered at the moment.

If covid disappears we stockpile, if not we treat. Oh and big pharma you can wait a bit as we can handle this first bit ourselves. They deserve all the success and recognition that is coming their way in the next 12 months.

That does appear to be the case Roots and is definitely the route the company is planning to take.

Peel, That price was straight from the horse mouth.

You really have to hold to the end now after those numbers!

Doc, He said stop asking about vaccines which is completely fair enough!

No probs Phyl. You would think in this day and age they could come up with a better algorithm.

Hopefully news soon for SAE on tidal and Uskmouth fronts. GL.

- All those that can never have a vaccine for medical reasons.

* above the midpoint prints as a buy...

Phyl,

LSE just takes the midpoint of the bid/ask. If the printed trade is above the midpoint it prints as a, if below it prints as a sell. It has no relation to whether the printed trade was a buy or a sell. You have to do some dummy quotes to get a better idea of the actual bid/ask prices.

not from HL

DD, I thought he said they have the only test for this so there is no competition yet.

Sphunken,

At the end of October the Recovery trial had recruited 1000 patients within 10 days. Hospitalisation has increased since then. Surely we can get the UK arm filled within a month.

1. How many people have been recruited to date on the home trial?

2. When is first dosing of the phase 3 trial expected?

Thats all I want to know.

Sorry missed the full extract.

In a September interview Medscape editor in chief Eric Topol pondered what counts as a recorded “event” in the vaccine trials. “We’re not talking about just a PCR [polymerase chain reaction test]-positive mild infection. It has to be moderate to severe illness to qualify as an event, correct?” he asked.8

“That’s right,” concurred his guest, Paul Offit, a vaccinologist who sits on the FDA advisory committee that may ultimately recommend the vaccines for licence or emergency use authorisation.

But that’s not right. In all the ongoing phase III trials for which details have been released, laboratory confirmed infections even with only mild symptoms qualify as meeting the primary endpoint definition. In Pfizer and Moderna’s trials, for example, people with only a cough and positive laboratory test would bring those trials one event closer to their completion. (If AstraZeneca’s ongoing UK trial is designed similarly to its “paused” US trial for which the company has released details, a cough and fever with positive PCR test would suffice.)

Me either, especially after reading the following in the BMJ last month regarding vaccine trial design and safety. Take the point below about the two current vaccines that have produced outstanding results!!

https://www.bmj.com/content/371/bmj.m4037

In a September interview Medscape editor in chief Eric Topol pondered what counts as a recorded “event” in the vaccine trials. “We’re not talking about just a PCR [polymerase chain reaction test]-positive mild infection. It has to be moderate to severe illness to qualify as an event, correct?” he asked.

But that’s not right. In all the ongoing phase III trials for which details have been released, laboratory confirmed infections even with only mild symptoms qualify as meeting the primary endpoint definition. In Pfizer and Moderna’s trials, for example, people with only a cough and positive laboratory test would bring those trials one event closer to their completion. (If AstraZeneca’s ongoing UK trial is designed similarly to its “paused” US trial for which the company has released details, a cough and fever with positive PCR test would suffice.)

This is interesting. Bella. Great work. Perhaps we will get some interim results from the UK first.

"It is worth bearing in mind that they need to sample certain types of patient as the NIHR piece refers to so there might be 20 sites that tests could be carried out at but patients must be picked on basis of meeting criteria needed for the test. It wouldn't be picking 4.5 patients in each site it would be meeting sample criteria by age, gender, previous condition etc who might present at any of the locations."

And yet the vaccine makers have not bothered to do this. At least we will know when the phase 3 results are produced they will be comprehensive and if successful EUA will be very quick.

Yep. Need some news to move this back where it belongs. Home trial final patient dosed might ignite it a bit.